Reports / Neurology Reports / RealTime Dynamix: Multiple Sclerosis EU
RealTime Dynamix: Multiple Sclerosis EU (bi-annual)
The EU multiple sclerosis (MS) market is more dynamic and complex than ever with several clinically distinct disease-modifying therapies (DMTs) currently available, including the recent launch of Roche’s Ocrevus, for early primary progressive MS (PPMS) and relapsing forms of MS (RMS), and Merck KGaA’s Mavenclad, an oral induction therapy for RMS. An active late-stage DMT pipeline holds the promise of a 2019 launch of Novartis’ Mayzent with a first-to-market secondary progressive MS (SPMS) label. Evolving practice guidelines recommend early treatment with high efficacy DMTs in highly active MS patients although neurologists’ beliefs and prescribing patterns do not appear to always be in sync.
RealTime Dynamix™: Multiple Sclerosis (EU) provides a twice-yearly analysis of key performance metrics, focusing on brand gains and losses, industry contact rates, familiarity and adoption rates of recently launched products, and awareness of products in development. Product perceptions, disease awareness and attitudes, practice management and other topics are rotated throughout the year to provide an ongoing probe of the crucial drivers of change. This ongoing, independent insights series allows marketing professionals to keep abreast of and quickly react to market changes by providing critical information that will support their commercial strategies in the MS space.
This bi-annual report has been fielded since Q3 2017.
Learn more about RealTime Dynamix™ reports here.
- How is the current and near-term landscape for MS market evolving? How does this differ by country?
- What are the critical opportunities and barriers to growth for each brand and class?
- How are newcomers, Mavenclad and Ocrevus, impacting the RMS market? With continued market penetration, where are neurologists using Ocrevus in the RMS treatment algorithm? Is Mavenclad perceived and used as a first-line option? Has Ocrevus grown the PPMS market segment?
- To what extent is generic glatiramer acetate use driven by neurologist choice versus market access pressure?
- How is the treatment algorithm changing with increasing oral DMT experience and expanding options within the monoclonal antibody DMT class?
- To what degree do neurologists have strong preferences for specific brands within the DMT classes? How are the DMTs delivering on the key attributes and on typical patient types?
- With fewer opportunities for personal interactions, what the best channels for industry to share product information with neurologists?
- What are neurologists’ perceptions of late-stage pipeline assets and how do they anticipate incorporating these products into their MS treatment?
- To what degree will the availability of Mayzent expand the SPMS segments or increase the switch rate during SPMS transition? What treatment patterns will differ between active versus not active SPMS patients?
Bayer (Betaferon), Biogen (Avonex, Plegridy, Tecfidera, Tysabri, Zinbryta*), Merck KGaA (Mavenclad*, Rebif), Sanofi (Aubagio, Lemtrada*), Novartis (Gilenya, Extavia), Roche (Ocrevus*, MabThera), Teva (Copaxone), multiple companies (i.e., rituximab*, glatiramer acetate*)
*May still be pending/reimbursement pricing in certain EU markets at time of fielding
AB Science (masitinib), Biogen [diroximel fumarate (with Alkermes)], Celgene (ozanimod), J&J/Actelion (ponesimod), MedDay (MD-1003), MediciNova (ibudilast), Novartis (Mayzent*, ofatumumab), TG Therapeutics (ublituximab)
*Could move to commercial products based upon regulatory outcomes
Preferential First-Line Use of Biogen’s Tecfidera and Continued Uptake of Merck KGaA’s Mavenclad Drives the Significant Increase in Oral Disease-Modifying Therapy Class Share in the European Multiple Sclerosis Market Over the Past Year – April 10, 2019
Uptake of Biogen’s Tecfidera and Increased Availability of Merck KGaA’s Mavenclad Fueling Significant Increase in Oral Disease-Modifying Therapy Share of Multiple Sclerosis Patients in Europe to the Detriment of Teva’s Copaxone – October 9, 2018